The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients).
Patsientide arv, kellel tekkisid DNA- kaksikheeliksi vastased antikehad, oli samuti suurem radioimmunoloogilise uuringu (15% Enbreliga ravitud ning 4% platseebot saanud patsientidest) ja Crithidia luciliae analüüsi põhjal (3% Enbreliga ravitud ja mitte ühelgi platseebot saanud patsientidest).